Menopausal Hormone Therapy in Women with Family History of Breast Cancer

Introduction to Menopausal Hormone Therapy

• The National Comprehensive Cancer Network recommends that Menopausal Hormone Therapy (MHT) should be used with caution in women with a family history of breast cancer, as it may increase their already elevated baseline risk, but it is not absolutely contraindicated unless there is a personal history of breast cancer or other specific contraindications 1, 2

Risk Assessment and Considerations

• MHT use should be approached with particular caution in women with increased genetic cancer risk, including those with BRCA1/2 mutations or strong family histories suggestive of genetic predisposition 1, 3

Decision-Making Algorithm

• Absolute contraindications to MHT include personal history of hormonally mediated cancers, abnormal vaginal bleeding, active or recent history of thromboembolic events, pregnancy, and active liver disease 1, 3
• The National Comprehensive Cancer Network suggests determining if the patient has early-age-onset breast cancer in family members, multiple breast primaries or breast and ovarian cancer in a single individual, two or more breast primaries in close relatives from the same side of the family, or known BRCA1/2 or other gene mutations associated with breast cancer risk 4

Alternative Therapies

• Non-hormonal options for managing menopausal symptoms, such as cognitive behavioral therapy for vasomotor symptoms and vaginal moisturizers and lubricants for vaginal dryness, should be tried before MHT in women with a family history of breast cancer 1, 2, 3, 5

Menopausal Hormone Therapy Usage

• If MHT is necessary, the lowest effective dose for the shortest duration possible should be used, and formulation should be carefully considered, with transdermal estrogen potentially being preferred over oral formulations due to lower VTE risk 3, 6
• Micronized progestin may be preferred over medroxyprogesterone acetate due to potentially lower breast cancer risk 6

Special Considerations

• Women with BRCA mutations who undergo risk-reducing salpingo-oophorectomy may safely use short-term MHT to manage menopausal symptoms, as studies indicate this is safe among healthy BRCA1/2 mutation carriers 2
• Custom compounded bioidentical hormones are not recommended as they lack data supporting claims of improved safety or efficacy 3, 6

Monitoring and Follow-up

• Women with a family history of breast cancer using MHT should undergo appropriate breast cancer screening according to guidelines and have regular follow-up to reassess the need for continued MHT 3, 7